Home Blog Page 23

ZEELOOL Launches French Summer Edit for Summer 2026

AUSTIN, Texas, June 5, 2026 /PRNewswire/ — ZEELOOL, the leading eyewear brand, has launched its long-awaited French Summer edit for Summer 2026. This collection of optical eyeglass frames and sunglasses draws inspiration from the creative theme of “One Frame, Two Lives”, providing both flexibility and fashion for all occasions. From morning commutes to coastal weekends, these frames are designed to move with you and elevate your summer look.


ZEELOOL French Summer Edit – One Frame, Two Lives

ZEELOOL French Summer Edit
ZEELOOL French Summer Edit

Presented in warm acetate, soft transparents and subtle metal details are five key silhouettes – Butterfly, Oval and Rectangle. Each style is carefully designed to be both stylish and practical, with the possibility of accommodating prescription lenses. This collection is the perfect blend of timeless French elegance and contemporary trends, making it a must-have for anyone ahead of the fashion curve.

“We’re so excited to launch our French Summer Edit for Summer 2026,” said ZEELOOL spokesperson. “This collection is all about celebrating the French way of life and bringing it into your everyday style. With our ‘One Frame, Two Lives’ concept our customers can seamlessly go from work to play, without having to sacrifice style or comfort.

To celebrate the launch, ZEELOOL is also offering a special promotion of “Buy 1, Get 50% Off Sunglasses.” It’s a great opportunity for customers to upgrade their eyewear collection and add a touch of French elegance to their summer wardrobe. The French Summer Edit is available for purchase now on ZEELOOL’s website, with international shipping options.

ZEELOOL is disrupting the eyewear fashion industry and offering its customers high quality and stylish options with the French Summer Edit. Experience the thrill of this collection and take your summer style to the next level with ZEELOOL’s “One Frame, Two Lives” concept. For more info and to shop the collection, visit ZEELOOL’s website today.

Zenerate and Pivotal Architecture Join Forces to Accelerate Early-Stage Real Estate Development Planning

LOS ANGELES, June 5, 2026 /PRNewswire/ — Zenerate, an AI-powered real estate feasibility platform, today announced a strategic partnership with Pivotal Architecture to enhance feasibility reporting services for real estate development projects.

The collaboration combines Zenerate’s proprietary AI technology with Pivotal Architecture’s extensive expertise in residential, mixed-use, and commercial projects. Together, the companies aim to help developers and architects evaluate site opportunities more efficiently and move from initial property assessment to viable development concepts with greater speed and confidence.

Early-stage feasibility is a critical component in the real estate development process. Before committing resources to acquisition, design, financing, or entitlement efforts, project teams must understand a site’s development potential, regulatory constraints, and overall project viability. Yet traditional feasibility studies often involve multiple service providers, resulting in a fragmented and time-consuming process.

Under the partnership, Zenerate will serve as the primary point of contact for clients, overseeing project intake, workflow coordination, service provider management, and report delivery. The company will offer a streamlined feasibility reporting service that can include zoning and site analysis, test fit, pro forma modeling, cost estimation, and professional renderings.

Pivotal Architecture will contribute architectural expertise and technical support throughout the feasibility process, including site evaluations, conceptual layouts, test-fit studies, and other design materials that help inform early-stage development decisions.

Together, the companies aim to simplify the feasibility process for land development and help development and design teams move from site evaluation to informed decision-making more efficiently.

Clients can submit project information through Zenerate’s online application form (https://www.zenerate.ai/report-service) and receive customized proposals tailored to their project requirements, deliverables, and timeline.

About Zenerate

Zenerate is an AI-powered real estate feasibility platform that helps developers and architects evaluate development opportunities faster. The platform supports early-stage feasibility workflows, including site planning, test fits, unit mix studies, parking layouts, design option generation, and pro forma analysis. Zenerate helps development and design teams explore multiple site scenarios quickly so they can make more informed decisions during acquisition, planning, and early design.

For more information, visit https://www.zenerate.ai.

About Pivotal Architecture

With a strong background in residential and commercial architecture, Pivotal Architecture specializes in multi-unit residential, mixed-use, and commercial projects. The firm’s portfolio includes past work on more than 10,000 residential units and over two million square feet of commercial space. Its collaborative approach focuses on synthesizing client goals with building site challenges, complex municipal requirements, constructability, and cost efficiency.

For more information, visit https://pivotal-arch.com/.

Notabene Flow Activates Hundreds of Customers, Enabling Stablecoin B2B Payments Across the Globe

Any payer holding funds at an institution on the Notabene Network can now complete a Notabene Flow payment with no additional integration required

NEW YORK, June 5, 2026 /PRNewswire/ — Notabene, the trust layer for global money movement, today announced that customers of hundreds of regulated digital asset institutions can now complete Notabene Flow payments directly from accounts they already use. The milestone extends Notabene Flow’s reach to the customers of every institution integrated on the Notabene Network — the largest global network of regulated digital asset institutions, spanning 2,000+ entities across 100+ jurisdictions and processing trillions of dollars of transaction volume annually.

The activation follows a network-wide rollout of Notabene Flow responder capabilities to Notabene’s existing customer base — the exchanges, custodians, payment providers, and banks already running Travel Rule-compliant multi-party flows on the Notabene Network. Any business that issues a Notabene Flow payment link today can expect the recipient to complete the transaction directly from their hosted wallet at one of these institutions, with no separate onboarding required on their end. Payers can also complete Notabene Flow payments using a self-hosted wallet through the Notabene platform.

“The value of a payment network comes down to reach — whether the person you’re trying to pay can actually receive it from wherever their funds are held,” said Pelle Braendgaard, CEO of Notabene. “Hundreds of live responders means that when a business sends a Notabene Flow payment link today, the recipient can pay from their existing account at an institution already on the network. Building that kind of reach on an open network, rather than a closed one, is what makes it genuinely useful at scale.”

Notabene Flow launched in September 2025 as the first open stablecoin payments network that authorizes every B2B invoice before it settles and reconciles it as it arrives — across any wallet, network, or jurisdiction. The network is built on the Transaction Authorization Protocol (TAP), an open messaging standard that any regulated institution can implement regardless of which custody or infrastructure provider, assets or blockchain they use.

Businesses can join the Notabene Flow network today to enable high-value cross-border B2B payments, using pull payments, structured invoicing, and Travel Rule-compliant multi-party payment flows at notabene.id/join-flow.

About Notabene

Notabene is the trust layer for global money movement. The Notabene network connects thousands of trusted counterparties, facilitating trillions of dollars in transaction volume annually across over 100 jurisdictions. Notabene provides industry-leading tools for stablecoin payment coordination, real-time transaction authorization, counterparty verification, and self-hosted wallet identification—helping institutions build trust into every transaction.

Learn more at notabene.id

Media Contact:
Clay Fain
VP Marketing
clay@notabene.id 

MicroAlgo Inc. Develops a Reconfigurable Simulation Technology of High-Precision, High-Throughput Scalable Quantum Algorithms

SHENZHEN, China, June 4, 2026 /PRNewswire/ — MicroAlgo Inc. (the “Company” or “MicroAlgo”) (NASDAQ: MLGO), today announced the development of an innovative high-precision, high-throughput reconfigurable simulation technology, aimed at providing effective solutions for the research and application of quantum algorithms.

The core of quantum computing lies in quantum bits (qubits), which can represent multiple states simultaneously, achieving parallel computing capabilities through quantum phenomena such as superposition and entanglement. However, the practical implementation of quantum computers is still in its early stages, facing numerous technical challenges. Currently, mainstream quantum computers, such as those based on superconducting qubits and ion traps, remain imperfect in terms of the number of qubits and error correction capabilities, making large-scale quantum computing difficult. Therefore, simulating quantum algorithms on classical computing platforms has become an important research approach. Through classical simulation, researchers can gain a deep understanding of the characteristics and performance of quantum algorithms, providing strong support for the development and application of actual quantum computers.

Traditional quantum algorithm simulation methods are typically based on the quantum circuit model, simulating the operation of each quantum gate step by step. While this approach is intuitively easy to understand, its computational complexity and resource demands grow exponentially when handling a large number of qubits, resulting in low simulation efficiency, significant hardware resource consumption, and excessively long simulation times. Therefore, developing efficient quantum algorithm simulation technology has become an urgent need.

MicroAlgo has proposed a reconfigurable simulation technology for quantum algorithms with high precision and high throughput. This technology is primarily based on two innovative simulation models: the arithmetic operation simplification model and the nuclear operation iteration model. The arithmetic operation simplification model reduces the complexity of quantum state operations by transforming the functionality of quantum circuits into basic arithmetic operations (such as multiplication and accumulation). MicroAlgo represents common quantum gate operations as equivalent arithmetic operations and uses precomputation and lookup table methods to quickly obtain the results of these operations. For complex operations, a dynamic generation approach is adopted, producing intermediate results as needed. This method not only reduces computational complexity but also enhances the computational speed and throughput of the simulation through parallel processing.

The nuclear operation iteration model, on the other hand, extracts the key operations of a quantum circuit and focuses on processing changes in quantum states, thereby avoiding the complex process of step-by-step simulation of the entire circuit. MicroAlgo first analyzes the quantum circuit to identify the key operations that have the greatest impact on quantum state evolution, then performs nuclear operation iterations on all input quantum states. This approach not only simplifies the computational process but also significantly improves simulation efficiency. By optimizing the design of the extracted nuclear operations and employing parallel processing methods, the simulation speed and throughput are further enhanced.

To fully leverage the advantages of these two simulation models, MicroAlgo has adopted a reconfigurable hardware architecture for the implementation of the simulator. The reconfigurable technology enables flexible allocation and utilization of hardware resources through dynamic hardware configuration adjustments, allowing the simulator to dynamically adjust the allocation of computing units and storage resources based on the requirements of different quantum algorithms, thereby improving the efficiency of hardware resource utilization. Additionally, to ensure the numerical precision of simulation results, MicroAlgo’s (NASDAQ: MLGO) simulator supports single-precision floating-point operations. Floating-point operations offer higher numerical precision and computational flexibility, making them suitable for handling complex quantum states and operations. Through a fully pipelined design, the simulator’s various computing units can continuously process data without interruption, further enhancing simulation efficiency and throughput.

To validate the performance of the simulation models and hardware architecture, MicroAlgo conducted simulation experiments on several classic quantum algorithms, including the Quantum Fourier Transform (QFT) and quantum wavelet transform. The experimental results demonstrate that MicroAlgo’s proposed simulation models significantly outperform traditional methods in terms of resource utilization and simulation time. For example, in the simulation experiments of the Quantum Fourier Transform, the arithmetic operation simplification model and the nuclear operation iteration model achieved a more efficient simulation process by reducing computational complexity and focusing on processing key operations, respectively. In the simulation of the quantum wavelet transform, MicroAlgo’s simulator, through its fully pipelined design and parallel processing, significantly reduced resource consumption and simulation time, proving its superiority in handling complex quantum algorithms.

As quantum computing research continues to advance, quantum algorithms are showing broad application prospects in fields such as scientific computing, cryptography, and materials science. This simulation technology provides strong support for the research and application of quantum algorithms, not only accelerating the development and testing of quantum algorithms but also laying the foundation for the practical application of quantum computers. In the field of scientific computing, quantum algorithms can significantly improve the efficiency of solving complex problems. MicroAlgo’s simulation technology enables researchers to efficiently simulate quantum algorithms on classical platforms, accelerating the development and validation of new algorithms and providing more possibilities for scientific computing.

MicroAlgo’s high-precision, high-throughput reconfigurable simulation technology for quantum algorithms has significant applications in the field of quantum computing cryptography, particularly in breaking traditional encryption algorithms. Through efficient simulation technology, researchers can test and optimize quantum cryptographic algorithms on classical platforms, enhancing the security and practicality of cryptography. Additionally, quantum algorithms hold broad application prospects in materials science, enabling the simulation and optimization of the quantum properties of materials. MicroAlgo’s simulation technology can assist researchers in efficiently simulating the quantum behavior of materials on classical platforms, promoting the discovery and application of new materials.

MicroAlgo’s high-precision, high-throughput reconfigurable simulation technology for quantum algorithms provides innovative solutions for the research and application of quantum computing. By integrating the arithmetic operation simplification and nuclear operation iteration simulation models, combined with reconfigurable technology, single-precision floating-point operations, and a fully pipelined design, the simulator achieves significant optimizations in resource utilization and simulation time. Experimental results demonstrate the feasibility and superiority of the simulator in running and testing various quantum algorithms. In the future, as quantum computing technology continues to advance, MicroAlgo’s simulation technology will continue to play a crucial role, providing robust support for the research and practical application of quantum algorithms, and driving the arrival of the quantum computing era.

About MicroAlgo Inc.

MicroAlgo Inc. (the “MicroAlgo”), a Cayman Islands exempted company, is dedicated to the development and application of bespoke central processing algorithms. MicroAlgo provides comprehensive solutions to customers by integrating central processing algorithms with software or hardware, or both, thereby helping them to increase the number of customers, improve end-user satisfaction, achieve direct cost savings, reduce power consumption, and achieve technical goals. The range of MicroAlgo’s services includes algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence services. MicroAlgo’s ability to efficiently deliver software and hardware optimization to customers through bespoke central processing algorithms serves as a driving force for MicroAlgo’s long-term development.

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of MicroAlgo, including those set forth in the Risk Factors section of MicroAlgo’s periodic reports on Forms 10-K and 8-K filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, MicroAlgo’s expectations with respect to future performance and anticipated financial impacts of the business transaction.

MicroAlgo undertakes no obligation to update these statements for revisions or changes after the date of this release, except as may be required by law.

Registration Now Open for Free Public Admission to Fifth Hong Kong Science Fair

Over five years, nearly 9,000 teachers and students have participated in the Fair to drive youth engagement in innovation and technology


HONG KONG SAR – Media OutReach Newswire – 4 June 2026 – Organised by the Hong Kong Innovation Foundation (‘HKIF’), the Fifth Hong Kong Science Fair (‘Science Fair’) will take place from 27 to 28 June 2026 at the Hong Kong Convention and Exhibition Centre. The event will showcase around 120 shortlisted teams from primary and secondary schools across Hong Kong, presenting creative inventions that integrate artificial intelligence with a diverse range of technology applications. With Sino Group as Principal Patron, the Innovation, Technology and Industry Bureau of the HKSAR Government (ITIB) as the Supporting Bureau, and the Hong Kong Council for Testing and Certification (HKCTC) as Strategic Partner, HKIF is also honoured to have, for the first time, invited the Foundation for the Development of Science and Technology in China as an Advisory Organisation. Representatives from the Foundation will attend the award ceremony to witness the announcement of this year’s winning teams. Consistently a major draw for the community, the Science Fair is now open for online registration with free admission, and the public is warmly invited to attend in person.

Since its launch in 2021, the Science Fair has attracted participation from over 400 local schools, engaging nearly 9,000 students and teachers from Primary 4 to Secondary 6. To date, more than 2,200 creative invention submissions have been received, and the event has established itself as a key platform for youth I&T exchange.
Since its launch in 2021, the Science Fair has attracted participation from over 400 local schools, engaging nearly 9,000 students and teachers from Primary 4 to Secondary 6. To date, more than 2,200 creative invention submissions have been received, and the event has established itself as a key platform for youth I&T exchange.

Following Hong Kong’s first astronaut, Dr Lai Ka-ying, into space, the local innovation and technology ecosystem has attracted even greater attention. This year’s Science Fair has specially incorporated aerospace engineering elements, enabling the public to learn about the daily work and challenges of payload specialists, gain insight into the reality of aerospace research and development, and spark greater interest among young people in space exploration. Dr Lai launched aboard the Shenzhou-23 manned spacecraft and is expected to remain in space for approximately six months to conduct space science experiments and maintenance tasks. Visitors can express their support and encouragement by creating message cards for her. In addition, UBTECH Robotics, a globally leading enterprise in embodied AI robotics, will participate in the exhibition, showcasing multiple humanoid robots and offering visitors the opportunity to experience the appeal of embodied intelligence up close.

Professor Sun Dong, JP, Secretary for Innovation, Technology and Industry of the HKSAR Government, stated: ‘The Hong Kong SAR Government is fully committed to developing Hong Kong into an international innovation and technology (I&T) centre, with talent being a key driver of this growth. Now in its fifth edition, the Hong Kong Science Fair – organised by the Hong Kong Innovation Foundation – has become an annual flagship I&T education event. It offers students a valuable platform to turn their innovative ideas into practice, deepen their interest and confidence in I&T, and help bring I&T into schools and the wider community, thereby fostering a more innovation-friendly atmosphere. I look forward to seeing more young people unleash their potential through this platform, pursue careers in I&T, and contribute to the high-quality development of Hong Kong and our nation.’

Mr Daryl Ng, SBS, JP, Chairman of the Hong Kong Innovation Foundation and Chairman of Sino Group, said ‘Innovation and technology are key to Hong Kong’s long-term sustainable development and are integral to the country’s 15th Five-Year Plan. It is vital for Hong Kong to strengthen its I&T capabilities and actively contribute to national development, as underscored by the historic moment when Dr Lai Ka-ying became Hong Kong’s first astronaut. We are encouraged to see growing recognition of I&T opening up new opportunities for young people aspiring to pursue scientific research. As the Hong Kong Science Fair enters its fifth edition, its growth has been made possible by the support of the HKSAR Government, industry partners, tertiary institutions, research organisations, and our panels of judges. This year, we are grateful for the guidance and support of the Foundation for the Development of Science and Technology in China. Moving forward, the Science Fair will remain committed to nurturing talent from an early age, bringing together all sectors to promote I&T and inspire more young people to pursue careers in science and technology.’

Professor Anderson Shum, MH, Chairman of Judging Panel, Hong Kong Science Fair, President of The Hong Kong Young Academy of Sciences, said, ‘The Science Fair adopts the format of “integrating competition with exhibition,” enabling students to translate their learning into tangible and verifiable outcomes. This plays an important role in nurturing Hong Kong’s youth I&T ecosystem. I am delighted to have served as a judge for this major event over the years, witnessing students progressively enhance their presentation skills, build confidence, and broaden their horizons through exchanges with experts, participation in workshops and showcasing their work to the public. The standard of participating projects continues to improve each year, with increasing integration of artificial intelligence and diverse technological applications across different fields. Scientific research is a journey that demands passion and perseverance, and the growth of young scientists often begins with curiosity during their primary and secondary school years. Through these exchanges, we hope to leverage the role-model influence of young scientists, inspiring more students to pursue I&T as their lifelong career. I look forward to seeing our younger generation continue to grow and excel in scientific research and innovation, and officially join the community of scientists in the near future to jointly drive Hong Kong’s I&T development.’

Mr Michael Tam, Chief Brand Officer of UBTECH, said, ‘Humanoid robots are among the most promising real-world embodiments of artificial intelligence, reflecting a future in which intelligent systems are deeply integrated with the physical world. As a global pioneer in humanoid robotics, UBTECH has remained at the forefront of innovation for more than 14 years, with a long-standing commitment to I&T education. The company is dedicated to translating advanced technologies into practical, accessible educational resources. Through collaboration with like-minded partners such as the Hong Kong Innovation Foundation, we aim to inspire greater interest and engagement among both teachers and students in humanoid robotics and artificial intelligence. We are committed to supporting the development of Hong Kong’s I&T education ecosystem, helping to nurture future-ready talent and build a strong, sustainable foundation for long-term growth.’

Since its launch in 2021, the Science Fair has attracted participation from over 400 local schools, engaging nearly 9,000 Primary 4 to Secondary 6 students and their teachers. To date, more than 2,200 creative invention submissions have been received and total attendance has exceeded 120,000 visitors. The Science Fair has gradually established itself as a key platform for youth innovation and technology (‘I&T’) exchange and one of Hong Kong’s most representative I&T education initiatives. This year’s response has been enthusiastic, with over 500 project submissions received. Following preliminary judging, around 120 shortlisted teams took part in a series of workshops and mentorship sessions, and will present their projects at the exhibition in late June to compete for top awards. Gold award-winning teams from each category will have the opportunity to participate in the International Exhibition of Inventions Geneva in Switzerland, fostering idea exchange with global I&T talents.

The Hong Kong Science Fair draws tens of thousands of visitors each year. During the exhibition period, the venue will be transformed into a catalyst for city-wide I&T inspiration. In addition to student showcases, five interactive zones will offer hands-on experiences, including DIY bubble bath bomb workshops, freezer-free slushie making, themed games celebrating the Science Fair’s fifth anniversary, and modified remote-controlled cars made from upcycled household appliances, allowing visitors of all ages to explore science and innovation through engaging and enjoyable activities.

  • Bulu Bulu Bubble Factory: Blending science with sensory experiences, visitors can mix and mould from scratch to create a delightful ‘bathroom blind box’.
  • Shake Shake Ice Factory: Applying the principle of freezing point depression, participants will see how temperature can be rapidly lowered using only salt, ice and water to create personalised slushies — all without a freezer.
  • Scan2Play: Scan the QR Code on your phone to join the themed game celebrating the Hong Kong Science Fair’s Fifth Anniversary.
  • Racing Homey Kart 2.0: Showcasing the spirit of upcycling and upgrades, visitors can transform old, small household appliances into remote-controlled racing cars and compete on a dedicated track.
  • UBTECH Robotics Base: Featuring a wide range of robots, this zone provides a comprehensive showcase of the integration of artificial intelligence with mechanical engineering.

To celebrate the Science Fair’s fifth edition, various special experiences will be introduced. The venue will feature a hidden Science Fair character treasure hunt and check-in activity, through which visitors can redeem curated gifts upon completion. Limited-edition souvenirs, including the ‘HKSF-5 Metal Standee Collection’ and the ‘Special Edition Robo K’ blind boxes, will also be available in limited quantities. All proceeds from the HKSF Bazaar, with no deduction, will go directly to charity to support local community technology initiatives.

The Fifth Hong Kong Science Fair Details:

  • Date: 27 to 28 June 2026 (Saturday and Sunday)
  • Time: 10:00 am to 6:00 pm
  • Venue: Hong Kong Convention and Exhibition Centre, Hall 3FG
  • Admission: Free of Charge (Pre-registration online is required)
  • Registration Website: https://reghksciencefair.org.hk/public

Photos download: https://shorturl.at/mgawb

Hashtag: #HKIF #ScienceFair

The issuer is solely responsible for the content of this announcement.

Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market

  • Everest Medicines has obtained exclusive rights for the clinical development and commercialization of Bejescin® (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan region, China.
  • Under the terms of the agreement, Everest Medicines will pay Mabworks an upfront payment of RMB 23 million and sales milestone payments of up to RMB 186 million. Mabworks will also be eligible to receive a share of gross profit in the region.
  • This collaboration will strengthen Everest Medicines’ presence in nephrology and autoimmune diseases across the Asia-Pacific region, creating synergies with its nephrology portfolio.

SHANGHAI, June 4, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (“Mabworks”), under which the Company has obtained exclusive rights for the clinical development and commercialization of Bejescin® (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast Asia, India, South Korea, Australia, New Zealand, Hong Kong SAR, Macao SAR, and Taiwan region, China.

This collaboration will strengthen Everest Medicines’ presence in nephrology and autoimmune diseases across the Asia-Pacific region, creating synergies with its nephrology portfolio. Leveraging its established and proven clinical development and commercialization capabilities, the company aims to advance the development of Bejescin® and support its launch in the Asia-Pacific region, while furthering its long-term strategy in the global innovative medicines market.

Under the terms of the agreement, Everest Medicines will pay Mabworks an upfront payment of RMB 23 million and sales milestone payments of up to RMB 186 million. Mabworks will also be eligible to receive a share of gross profit in the region.

Bejescin® (MIL62, Obinutuzumab beta Injection) is a novel third-generation anti-CD20 monoclonal antibody. It was approved in China in February 2026 for the treatment of neuromyelitis optica spectrum disorder (NMOSD), becoming the first CD20 antibody approved for this indication globally and the first domestically developed therapy in China. The New Drug Application (NDA) for primary membranous nephropathy (PMN) is currently under Priority Review by the National Medical Products Administration (NMPA), with the potential to become the first approved targeted therapy for PMN worldwide. Bejescin® is also in Phase III trials for systemic lupus erythematosus (SLE) and follicular lymphoma (FL), with potential for further expansion into other autoimmune indications.

“We are delighted to collaborate with Mabworks on Bejescin®. As the first CD20 antibody approved globally for NMOSD, Bejescin® has demonstrated strong clinical potential and significant opportunities in nephrology and autoimmune diseases,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “This collaboration strengthens Everest’s portfolio in these therapeutic areas and complements our existing pipeline. With our expertise in clinical development and commercialization, we are confident in advancing Bejescin® across the Asia-Pacific region, bringing this innovative therapy to more patients and improving access. At the same time, we are committed to further strengthening Everest Medicines’ presence in the Asia-Pacific and global innovative medicines market.”

“We are thrilled to announce our partnership with Everest Medicines on Bejescin® across the Asia-Pacific region. As the first approved CD20-targeted therapy for NMOSD worldwide and the potential global first targeted therapy for PMN, Bejescin® possesses exceptional product competitiveness and market potential.” said Mr. Luning Chen, President of Mabworks. “Since its launch in Mainland China, Bejescin® has achieved outstanding commercial performance. This collaboration will further strengthen Bejescin®‘s commercial network and brand influence across the Asia-Pacific region, bringing ‘New Hope’ to more patients with renal and autoimmune diseases.” 

Bejescin® has shown meaningful clinical and therapeutic benefits across nephrology and multiple autoimmune disease areas, with potential for further indication expansion. Its development in NMOSD, PMN, and SLE is expected to provide more innovative treatment options for patients.

NMOSD is a debilitating autoimmune disorder targeting the central nervous system characterized by high recurrence and disability rates, predominantly affecting young and middle-aged women. The disease typically presents acute or subacute onset and can progress rapidly, with approximately 90% of patients relapsing within three years. Severe cases may result in blindness or paralysis. Bejescin® has demonstrated a significant reduction in relapse risk as a monotherapy, with strong efficacy data underscoring both its clinical value and the convenience.

PMN is one of the most common pathological types of adult nephropathy, with approximately 30%-40% of patients progressing to end-stage renal disease (ESRD) within 5 to 15 years. Globally, there are no approved targeted therapies for PMN. Phase III clinical data demonstrated that Bejescin® monotherapy provides significant advantages across multiple efficacy endpoints including complete clinical remission, complete immunological remission and overall clinical remission. Furthermore, Bejescin® showed a favorable safety and tolerability profile, together with a convenient dosing regimen. Following initial treatment, patients require only one intravenous infusion every six months, reducing treatment burden and supporting long-term treatment adherence.

SLE is a chronic, systemic autoimmune disease that primarily affects young women. For this indication, Bejescin® is in Phase III clinical trial and offers the potential for administration every 24 to 28 weeks, addressing the need for long-acting therapies and providing an improved treatment option for patients with SLE.

About Bejescin® (MIL62)

Bejescin® (MIL62, Obinutuzumab beta Injection) is a novel 3rd-generation anti-CD20 monoclonal antibody with a unique competitive position in the market, and has been approved by NMPA for marketing in China for the treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD), becoming the world’s first CD20-targeted antibody therapy approved for NMOSD and the first approved domestically-developed therapy for this indication in China.

In October 2025, Bejescin® was granted Breakthrough Therapy Designation (BTD) by NMPA, becoming the first domestically developed therapy for the kidney disease to receive this designation in China. Bejescin®‘s New Drug Application (NDA) for this indication is currently under the NMPA’s Priority Review, positioning it to potentially become the first approved targeted therapy for PMN worldwide.

About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.

About Mabworks

Beijing Mabworks Biotech Co., Ltd. is a biopharmaceutical company in China dedicated to discovering and developing innovative and differentiated antibody therapies, committed to becoming a world-class biopharmaceutical innovator with core products and sustained R&D capabilities. Our mission is to translate scientific breakthroughs in immunology and biology into novel antibody therapies that target a wide range of autoimmune diseases and oncology, addressing significant unmet medical needs and market potential in China and globally. We will leverage this opportunity to continuously provide innovative and affordable treatment solutions for patients.

Forward-Looking Statements
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law

Robo.ai Subsidiary Neurovia AI to Participate as Official Government AI Cybersecurity Partner at The 3rd Government Cybersecurity Summit

ABU DHABI, UAE, June 4, 2026 /PRNewswire/ — Robo.ai Inc. (NASDAQ: AIIO) announced today that its wholly-owned subsidiary, Neurovia AI, will participate in The 3rd Government Cybersecurity Summit as an Official Government AI Cybersecurity Partner. Company Chief Technology Officer Mansoor Ali Khan has been invited to attend the event and will deliver a speech on “Building Trusted Visual Intelligence Infrastructure in the AI Era.” 


As digital transformation accelerates across the UAE’s government and public sector, cybersecurity remains a top national priority. With cyber threats becoming increasingly sophisticated, from AI-powered attacks to critical infrastructure vulnerabilities, the need for collaboration, innovation, and resilience has never been greater. The 3rd Government Cybersecurity Summit will bring together UAE government leaders, regulators, global cybersecurity experts, and technology innovators to share insights, showcase strategies, and drive secure digital growth.

The core topic of the upcoming address by Mr. Khan is “Building Trusted Visual Intelligence Infrastructure in the AI Era.” As artificial intelligence integrates into the physical world during the next development cycle, visual data has emerged as a national strategic infrastructure asset comparable to power grids and communication networks, representing a distinct architectural challenge for future AI advancement. Mr. Khan will present an analysis based on practical business scenarios, addressing structural challenges within current data architectures regarding computing energy consumption, real-time processing capabilities, and underlying data security under real-world operational loads.

About Robo.ai Inc.

Robo.ai Inc. (NASDAQ: AIIO) is a technology company focused on developing an artificial intelligence machine economy platform. Through the systematic integration of AI software, intelligent hardware, and smart assets, the company builds a unified AI operating system and an empowered ecosystem, delivering hardware-software integrated infrastructure solutions for global government and enterprise clients.

About Neurovia AI Limited

Neurovia is an AI visual data processing and compression technology company operating as a wholly-owned subsidiary of Robo.ai. Utilizing its core platform, NeuroStream™, the company focuses on AI-native compression and edge computing technologies to resolve transmission and computing bottlenecks associated with massive machine data, establishing a low-latency, high-efficiency data foundation for physical AI applications.

Forward-Looking Statements
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from expectations. For a discussion of risks and uncertainties, please refer to Robo.ai Inc.’s SEC filings.

Robo.ai Inc. Corporate Communications
Email: pr@roboai.io 
Website: www.roboai.io

Neurovia AI Corporate Communications
Email: info@neuroviaai.ae 
Website: www.neuroviaai.ae

Robo.ai Subsidiary Neurovia AI to Participate as Official Government Al Cybersecurity Partner at The 3rd Government Cybersecurity Summit

ABU DHABI, UAE, June 4, 2026 /PRNewswire/ — Robo.ai Inc. (NASDAQ: AIIO) announced today that its wholly-owned subsidiary, Neurovia AI, will participate in The 3rd Government Cybersecurity Summit as an Official Government Al Cybersecurity Partner. Company Chief Technology Officer Mansoor Ali Khan has been invited to attend the event and will deliver a speech on “Building Trusted Visual Intelligence Infrastructure in the AI Era.” 


As digital transformation accelerates across the UAE’s government and public sector, cybersecurity remains a top national priority. With cyber threats becoming increasingly sophisticated, from AI-powered attacks to critical infrastructure vulnerabilities, the need for collaboration, innovation, and resilience has never been greater. The 3rd Government Cybersecurity Summit will bring together UAE government leaders, regulators, global cybersecurity experts, and technology innovators to share insights, showcase strategies, and drive secure digital growth.

The core topic of the upcoming address by Mr. Khan is “Building Trusted Visual Intelligence Infrastructure in the AI Era.” As artificial intelligence integrates into the physical world during the next development cycle, visual data has emerged as a national strategic infrastructure asset comparable to power grids and communication networks, representing a distinct architectural challenge for future AI advancement. Mr. Khan will present an analysis based on practical business scenarios, addressing structural challenges within current data architectures regarding computing energy consumption, real-time processing capabilities, and underlying data security under real-world operational loads.

About Robo.ai Inc.

Robo.ai Inc. (NASDAQ: AIIO) is a technology company focused on developing an artificial intelligence machine economy platform. Through the systematic integration of AI software, intelligent hardware, and smart assets, the company builds a unified AI operating system and an empowered ecosystem, delivering hardware-software integrated infrastructure solutions for global government and enterprise clients.

About Neurovia AI Limited

Neurovia AI is an AI visual data processing and compression technology company operating as a wholly-owned subsidiary of Robo.ai Inc. (NASDAQ: AIIO). Utilizing its core platform, NeuroStream™, the company focuses on AI-native compression and edge computing technologies to resolve transmission and computing bottlenecks associated with massive machine data, establishing a low-latency, high-efficiency data foundation for physical AI applications.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations; for detailed information, please refer to the relevant disclosure documents filed by Robo.ai Inc. with the U.S. Securities and Exchange Commission.

Media Contacts

Robo.ai Inc. Corporate Communications
Email: pr@roboai.io
Website: www.roboai.io

Neurovia AI Corporate Communications
Email: info@neuroviaai.ae
Website: www.neuroviaai.ae